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Abstract
Background: Mutations of TCF4, which encodes a basic helix-loop-helix transcription factor, cause Pitt-Hopkins
syndrome (PTHS) via multiple genetic mechanisms. TCF4 is a complex locus expressing multiple transcripts by
alternative splicing and use of multiple promoters. To address the relationship between mutation of these
transcripts and phenotype, we report a three-generation family segregating mild intellectual disability with a
chromosomal translocation disrupting TCF4.
Results: Using whole genome sequencing, we detected a complex unbalanced karyotype disrupting TCF4
(46,XY,del(14)(q23.3q23.3)del(18)(q21.2q21.2)del(18)(q21.2q21.2)inv(18)(q21.2q21.2)t(14;18)(q23.3;q21.2)(14pter®
14q23.3::18q21.2®18q21.2::18q21.1®18qter;18pter®18q21.2::14q23.3®14qter). Subsequent transcriptome sequencing,
qRT-PCR and nCounter analyses revealed that cultured skin fibroblasts and peripheral blood had normal expression
of genes along chromosomes 14 or 18 and no marked changes in expression of genes other than TCF4. Affected
individuals had 12–33 fold higher mRNA levels of TCF4 than did unaffected controls or individuals with PTHS.
Although the derivative chromosome generated a PLEKHG3-TCF4 fusion transcript, the increased levels of TCF4
mRNA arose from transcript variants originating distal to the translocation breakpoint, not from the fusion transcript.
Conclusions: Although validation in additional patients is required, our findings suggest that the dysmorphic
features and severe intellectual disability characteristic of PTHS are partially rescued by overexpression of those
short TCF4 transcripts encoding a nuclear localization signal, a transcription activation domain, and the basic
helix-loop-helix domain.
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Background
Intellectual disability (ID) is characterized as a significant
deficit in intellectual functioning and in adaptive, concep-
tual, practical, and social skills [1], beginning before the
age of 18 years. Depending on the ascertainment method-
ology and definition, the prevalence of ID in the general
population is 1–3 % in industrialized countries [2–5].
Despite the prevalence and morbidity of ID, its physio-
logic bases remain poorly understood. Identified causes in-
clude environmental, epigenetic, and genetic factors [6, 7].
At a cellular level, these factors affect neuronal prolifera-
tion, migration, arborization, synaptogenesis, function, or
viability [7–9].
Normal brain development involves the precise orches-
tration of several processes. Derailment of these processes
by either a genetic or environmental insult causes cogni-
tive and other neurodevelopmental disorders. Consistent
with neurodevelopment being highly dependent on the
choreographed expression of genes regulating neuronal
development, an increasing number of cognitive disorders
have been recently recognized to be attributable to muta-
tions in regulators of gene expression [10–14].
Among the mutated chromatin regulators and tran-
scription factors associated with ID is transcription factor
4 (TCF4). TCF4 is transcribed from multiple promoters
and alternative splice transcripts resulting in at least 18
different protein isoforms [15]. TCF4, via its interactions
with other proteins, modulates an intricate combinatorial
regulatory circuit during central nervous system (CNS)
development [16]. Several splice variants show differential
subcellular distribution [15]. TCF4 encodes for class I
basic helix-loop-helix (bHLH) proteins that function as
transcriptional regulators when they heterodimerize with
tissue-restricted class II bHLH proteins [17].
Class II bHLH transcription factors co-expressed or
interacting with TCF4 during neurodevelopment include
Math1, a proneural protein expressed in the differentiating
neuroepithelium [18–20]; HASH1, a protein necessary for
the formation of distinct neuronal circuits within the CNS,
especially the telencephalon [21]; neuroD2, which plays
important roles in neuronal differentiation and survival
[22]; Id1, which is a homolog of proteins required for cor-
rect patterning in neurogenesis [23]; and Olig2, a regulator
of ventral neuroectodermal progenitor cell fate [24–26].
Mono-allelic mutations or genomic deletions of TCF4
cause Pitt-Hopkins syndrome (PTHS) [27–30]. PTHS has
an estimated prevalence of 1 in 34,000 to 1 in 41,000 [31]
and is characterized by severe ID, facial dysmorphism,
episodes of hyperventilation, acquired microcephaly,
seizures, happy disposition, and repetitive movements.
Analysis of the functional consequences of PTHS-
associated TCF4 mutations has found that not all deletions
and truncations of TCF4 result in complete loss-of-
function. Also, reading-frame elongating and missense
mutations can cause a range of outcomes from subtle func-
tional deficiencies to dominant-negative effects [30]. Con-
sequently, PTHS-associated mutations variably impair the
functions of TCF4 by diverse mechanisms and thereby
contribute to the phenotypic variability. Herein, we further
characterize the phenotypic variability and better define
the molecular mechanisms underlying the ID associated
with a balanced translocation interrupting TCF4 and segre-
gating with mild ID in three generations.
Subjects
Human subjects
The individuals or guardians of the individuals participat-
ing in this study gave informed consent approved by the
Institutional Review Board (protocol 76-HG-0238) of the
National Human Genome Research Institute. Two indi-
viduals with classic features of PTHS provided control
blood and/or skin biopsy samples. They were a 14-year-
old boy (UDP_10086; PTHS-1) with the mutation NM_00
1083962.1:c. [1650–1 G > A];[=], an established cause of
PTHS and a splice acceptor mutation likely causing skip-
ping of exon 18 and encoding p.Ser550Argfs*84 [32], and
a 7-year-old girl (UDP_499; PTHS-2) with the mutation
NM_001083962.1 (TCF4):c.[1726 C > T];[=] that encodes
p.Arg576*.
Clinical report
The proband (UDP_4765; III-3, Fig. 1a) was born to non-
consanguineous parents of mixed European descent and
with a family history of miscarriages and intellectual
disability. Exposures during the pregnancy included venla-
faxine, a serotonin-norepinephrine reuptake inhibitor, and
approximately 10 cigarettes per day. The proband was
born at term following an uncomplicated pregnancy by
spontaneous vaginal delivery. His birth weight, length and
head circumference were 4.1 kg (92nd centile), 54.5 cm
(99th centile), and 35 cm (66th centile), respectively. His
Apgar scores were 9 at 1, 5 and 10 min. There were no
neonatal complications or health problems during the first
year of life.
At age 14 months, his parents noted delayed develop-
ment. He scooted at about 12 months and walked without
support at 18 ½months. At the age of 2 years, he had 5
meaningful words and communicated predominantly by
showing displeasure. At 27 months, his skills were at the
level of a 15 to 18 month old; autism spectrum was ruled
out. At 4 years 4 months, assessment with the Wechsler
Preschool and Primary Scales of Intelligence – Third Edi-
tion (WPPSI-III) and Vineland Adaptive Behaviour Scale
– Second Edition (Vineland-II), Survey Interview Form
showed an uneven profile for verbal, nonverbal and
language skills ranging from average to below average. His
overall intellectual and adaptive functioning were below
average for his age.
Maduro et al. Orphanet Journal of Rare Diseases  (2016) 11:62 Page 2 of 15
On physical examination at 28 months of age, he had
diminished social interaction and had a height of 97.5 cm
(98th centile), a weight of 15 kg (90th centile), and a head
circumference of 50 cm (82nd centile). His dysmorphic
features included plagio- and brachycephaly, prominent
glabella, high anterior hairline, hypertelorism, upslanting
palpebral fissures, bilateral epicanthal folds, bulbous nasal
tip, prominent columella, large (6.0 cm, 97th centile)
cupped ears with a simple helix, a high arched palate, a
prominent chin, mildly hypoplastic zygomatic arch, and a
pectus carinatum (Fig. 1b-d). He also had a left single
palmar crease, prominent finger pads, 5th finger clinodac-
tyly, bilateral hallux valgus and clinodactyly of toes 3 to 5.
On neurologic exam he had normal strength and deep
tendon reflexes, mildly decreased central tone and a wide
based gait.
The proband’s father (UDP_4637; II-1, Fig. 1a) had a
similar history of developmental delay and impaired
speech development. He finished high school with assist-
ance and worked in a fast food restaurant. Formal neuro-
cognitive testing at age 31 years using Wechsler Adult
Intelligence Scale, Fourth Edition (WAIS-IV) and Adult
Self-Report (ASR) for Ages 18–59 revealed mild intellec-
tual disability with nonverbal reasoning significantly lower
than verbal reasoning. On physical exam, his height was
173 cm (31st centile), and his head circumference was
57 cm (56th centile). His dysmorphic features included
mild plagiocephaly, a high forehead, high anterior hairline,
upslanting palpebral fissures, simple ear helices, promin-
ent chin, high arched palate, left single palmar crease, and
prominent finger pads (Fig. 1e, f ). His neurologic examin-
ation was normal.
The proband’s paternal grandmother (UDP_4638; I-2,
Fig. 1a) had clinical depression and had undergone mul-
tiple surgeries for keratoconus. Her height measured
158.4 cm (23rd centile), and her head circumference was
53.5 cm (22nd centile). She had a high forehead, bulbous
nasal tip, and mild proptosis (Fig. 1g, h). At age 53 years,
her neurologic examination was unremarkable. Formal
testing by WAIS-IV, ASR and Wechsler Memory Scale –
Fourth Edition (WMS-IV) revealed a mild intellectual dis-
ability as well as verbal and visual memory impairments.
Results of additional investigations
Normal laboratory investigations for the proband included
a complete blood count and blood electrolytes, lipid pro-
file, liver and kidney function tests, and blood levels for
ammonia, lactate, thyroid stimulating hormone and go-
nadotropic steroids. He also had unremarkable plasma
amino acid and urine organic acid profiles and a normal
skeletal survey and bone age. He tested negative for an
FMR1 repeat expansion. Chromosome analysis revealed an
apparently balanced translocation, 46,XY, t(14;18)(q22;q21)
and chromosomal microarray analysis (GenomeDXv2.0)
found no clinically significant copy number variants. The
proband’s father and paternal grandmother had the same
Fig. 1 Clinical photographs of the proband (arrow, III-3), his affected father (II-1) and affected paternal grandmother (I-2). (a) Family pedigree.
Affected individuals are shown by black symbols. (b, c) Frontal and profile head photographs of the proband at age 2.4 years. (d) Profile head
photograph of the proband at age 3.4 years. (e, f) Frontal and profile head photographs of the proband’s father at age 30 years. (g, h) Frontal
and profile head photographs of the proband’s paternal grandmother at age 53 years
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chromosome translocation. A brain MRI performed on the
proband’s father showed no structural or myelination
abnormalities.
Methods
Characterization of the cytogenetically identified transloca-
tion and delineation of the potential mechanism of disease
was conducted by a series of molecular analyses that
included whole genome and transcriptome sequencing
followed by validation studies (Additional file 1: Figure S1).
Nucleic acid extraction
Genomic DNA was extracted from peripheral whole blood
using the Gentra Puregene Blood kit (Qiagen, Valencia,
CA) per the manufacturer’s protocol. Total RNA was
extracted from cultured skin fibroblasts using the RNeasy
Mini Kit (Qiagen, Valencia, CA) per the manufacturer’s
protocol. Total RNA from patient and control peripheral
whole blood samples was purified using the QuickGene
810 automated extraction machine (Autogen, Holliston,
MA) with an on column DNase digestion. The quality and
quantity of RNA was verified using an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA) and Nano-
Drop 8000 (Thermo Scientific, Waltham, MA).
SNP Chip analysis
The Illumina GenomeStudioTM software (V2011.1, Illu-
mina, San Diego, CA) was used to define the population
frequency of the B allele (PFB) statistics for 662 samples
from unrelated Undiagnosed Diseases Program (UDP)
individuals. Samples were run on the Illumina Human
OmniExpress-12v1_A chip and the resulting PFB file was
filtered for mitochondrial and chromosomal 0 SNP data.
Post-filtering, GenTrain score (clustering algorithm score),
genotype, B Allele Frequency (BAF), and log R Ratio (LRR)
for the proband were generated and exported. The proband
input file was run against the filtered PFB file using
PennCNV [33] with thresholds of 2, 5, or 10 SNPs to gen-
erate threshold specific copy number variant (CNV) calls.
All CNV calls were manually inspected and validated
for accuracy. Each copy number (CN) call position was
entered into the Illumina Genome Viewer (GenomeStu-
dioTM) and inspected with BAF and LRR plots for the
proband. Call authenticity was verified by comparing
normalized intensity of the A and B allele Cartesian co-
ordinates of the proband to rest of population in the
dataset. Illumina GenomeStudioTM Genotyping Module
generated normalized intensity values.
Whole-genome sequencing
Patient blood genomic DNA libraries were prepared and
sequenced according to Illumina (Illumina., San Diego,
CA) paired-end sequencing service protocols. Illumina’s
service package consisted of short-insert (308 median
fragment length) paired-end reads from one library with
100 bp read length. The library was barcoded and se-
quenced on 2 flow-cells (3 lanes) of Illumina HiSeq2000
platform and produced >89 billion high-quality bases (Add-
itional file 2: Table S1). Preliminary bioinformatics align-
ment analysis of the whole-genome sequencing data was
based on the Illumina pipeline (CASAVA 1.8). CASAVA
performed multi-seed and gapped alignments on human
reference sequence (NBCI Build 37; hg19). Sequences with
more than two mismatches and duplicated sequences cor-
responding to PCR amplification bias were excluded (Add-
itional file 3: Table S2). This left a total of 3,697,786 SNVs
with a heterozygous : homozygous non-reference ratio of
1.5 (Additional file 1: Table S3).
Detection of structural variations from whole-genome se-
quence data
Inter- and intra-chromosomal structural variations (SVs)
from the Illumina ELAND alignments were detected with
BreakDancer (version 1.1) and an in-house program,
BREAKER (Cherukuri PF, et al. unpublished data); SVs
were called with stringent criteria (−q 35 -r 2). BreakDan-
cer calls were filtered to include only SV calls in which ei-
ther plus or minus strand reads were at maximum 60 at
both breakpoints and were supported by at least 12 plus
or minus strand reads. The maximum cutoff was per-
formed to discard regions with suspiciously high sequen-
cing depth. BreakDancer calls with scores of 99 and higher
were included in further analysis. These high confidence
SV calls were filtered against (1) DGV high-throughput se-
quencing variants (UCSC track table), (2) Segmental Dupli-
cations (UCSC track table), and (3) HiSeq depth regions
(top 5 % UCSC track table). In steps 1, 2 and 3, an SV call
was filtered out if at least one of the breakpoints was
located within a ±500 bp window of a repetitive genomic
region (in case of a translocation, a 1001 bp window cen-
tered on the breakpoint). These SV candidate calls were
visually inspected with IGV and validated. This method-
ology found 22 putative insertions, deletions and inversion
candidates. Of these candidates, 5 were within genes (4
autosomal; 1 X-linked), and two interrupted a protein cod-
ing sequence:MIER1 and QPCT. Eighty-four percent of the
BreakDancer calls were manually assessed as false positives
after the systematic filtering. Single short-reads mapped
across the candidate inter-chromosomal translocation
break-point: chr14:chr18.
Tissue culture
Skin fibroblasts were obtained from skin biopsies. Both
affected fibroblasts and unaffected control fibroblasts were
grown in high-glucose DMEM medium with L-glutamine
(Life Technologies, Carlsbad, CA) supplemented with
10 % fetal bovine serum and 1 % Antibiotic-Antimycotic
(Life Technologies, Carlsbad, CA). Cultured fibroblasts
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were incubated in a humidity-controlled environment at
37 °C, with 95 % O2 and 5 % CO2. The medium was
exchanged for fresh medium every 3 days, and the cells
were used before passage 10.
RNA-seq Method
Poly-A selected RNA-seq libraries were constructed from
1 μg mRNA using the Illumina TruSeq RNA Sample Prep
Kits, version 2 (Illumina, San Diego, CA). The resulting
cDNA was fragmented using a Covaris E210. Library
amplification was performed using 8 cycles to minimize
the risk of over-amplification. Unique barcode adapters
were applied to each library. Libraries were quantitated by
qPCR using the KAPA Library Quantification Kit (KAPA
Biosystems) and pooled in an equimolar ratio. The pooled
libraries were sequenced on a GAiix. At least 40 million
101-base read pairs were generated for each individual
library. Data were processed using RTA 1.12.4.2 and
CASAVA 1.8.2.
Transcriptome data processing and data analysis
Transcriptome fastq reads (phred33-scaled) were mapped
onto the human genome assembly hg19 using Bowtie2 in
TopHat2 (v.2.0.3) [34, 35]. Pre-computed human refer-
ence sequence (NBCI Build 37; hg19) Bowtie2 index files
were used as the index files for read mapping. The UCSC
known gene splice junction library (GTF file) was used for
splice-read mapping; in addition, the fusion-search param-
eter switch was turned on to enable gene-fusion derived
transcript discovery. Transcript assembly, abundance esti-
mates and differential expression analyses were performed
using Cufflinks2 (v2.2.1) and Cuffdiff2 (v2.2.1) [35, 36].
Differential gene expression comparisons were run without
biological replicates; therefore biological sample gene vari-
ance could not be estimated. Differential expression was
calculated as fold-changes in gene expression (measured as
fragments per kilobase mapped (FPKM)). Pseudo-count of
FPKM 1 was added to all FPKM values to minimize infla-
tion of differential gene expression log-likelihood ratios
(base 10). Local neighborhood gene-differential analysis
was performed at chromosomal breakpoint junctions, using
Pearson correlation coefficient to detect anti-correlated
gene expression signature deviation from expectation.
Analysis of gene expression on chromosomes 14 and 18
The Pearson correlation coefficient of gene expression on
chromosomes 14 and 18 was calculated using all-possible
pairs (N2) resulting from a window of 3 genes. The meth-
odology is described in the Additional file 1.
PCR amplification
Genomic DNA sequences of interest were amplified
by polymerase chain reaction using the listed primers
(Additional file 1: Table S4), genomic DNA and Qia-
gen HotStar Plus Taq polymerase under conditions:
95 °C x 5 min denaturation followed by 40 cycles of
95 °C x 30 s, 55 °C x 30 s, 72 °C x 30 s.
Sanger sequencing
Residual primers and nucleotides were removed by incu-
bation with ExoSAP-IT (USB, Cleveland, OH). The ampli-
cons were sequenced by Macrogen (Rockville, MD) using
BigDye terminator chemistry and compared to the human
reference sequence (NCBI 37/hg19) using Sequencher
(GeneCodes, Ann Arbor, MI).
Reverse transcription polymerase chain reaction and
quantitative real-time polymerase chain reaction
For cultured fibroblasts, complementary DNA (cDNA)
synthesis was performed on 2 μg of total RNA using the
OmniScript RT Synthesis kit (Qiagen, Valencia, CA) and
Oligo dT23 Anchored Primers (Sigma, St. Louis, MO). The
cDNA sequence was verified by PCR analysis using the
listed primers (Additional file 1: Table S5), HotStar Plus Taq
polymerase (Qiagen, Valencia, CA) and 100 ng of cDNA
under conditions: 95 °C × 5 min denaturation followed by
40 cycles of 95 °C × 30 s, 60 °C × 30 s, 72 °C × 30 s.
For peripheral blood, cDNA synthesis was performed on
40 ng of total RNA using the SensiScript RT kit (Qiagen,
Valencia, CA) and Oligo dT23 Anchored Primers (Sigma,
St. Louis, MO). The cDNA sequence was verified by PCR
analysis using the listed primers (Additional file 1: Table
S5), HotStar Plus Taq polymerase (Qiagen, Valencia, CA)
and 80 ng of cDNA under conditions: 95 °C × 5 min
denaturation followed by 40 cycles of 95 °C × 30 s, 60 °C ×
30 s, 72 °C × 30 s.
Quantitative real-time PCR was performed on 80 ng of
cDNA, the listed primers (Additional file 1: Table S5) and
the QuantiFast SYBR Green PCR Kit (Qiagen, Valencia,
CA), and analyzed with the ABI 7500 Fast Real-Time PCR
System (Life Technologies, Carlsbad, CA). Target amplifi-
cation was normalized to that of GAPDH and shown as
expression relative to control.
Digital droplet PCR
Digital droplet PCR analysis was performed on 50 ng of
cDNA derived from patient and control fibroblast RNA
using TaqMan Genotyping Mastermix (Life Technologies,
Carlsbad, CA) and TaqMan Gene Expression Assay for
rs1261084 (Life Technologies, Carlsbad, CA) under condi-
tions: 95 °C x 10 min denaturation followed by 40 cycles
of 95 °C × 15 s, 60 °C × 60 s both with a ramp speed of
0.5 °C per second. The amplified products (4 million drop-
lets per sample) were read on the RainDrop Digital PCR
System (RainDance Technologies, Billerica, MA) and
analyzed using the Raindrop Analyst software. Results
were normalized to control fibroblasts.
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nCounter gene expression assay
The nCounter Gene expression assay was performed on
100 ng of total RNA derived from human blood peripheral
leukocytes or cultured fibroblasts from the patient, PTHS
controls, and unaffected controls (Clontech, Mountain
View, CA). The RNA samples were hybridized at 65 °C
for a minimum of 12 h to the Capture and Reporter
probesets (nanoString Technologies, Seattle, WA) that
were designed to include the listed TCF4 transcript vari-
ants (Additional file 1: Table S6). These complexes were
immobilized onto a cartridge and analyzed by the nCounter
Digital Analyzer (nanoString Technologies, Seattle, WA).
Geometric means were used to calculate the normalization
factor and data were normalized to GAPDH expression.
The results were analyzed, calculated relative to control
gene expression in blood derived samples, and reported as
the log2 ratio relative to control TCF4 transcript levels.
Results
TCF4 is disrupted by a complex chromosomal
translocation that segregates with ID in three generations
To identify genes disrupted by the apparently balanced
translocation between chromosomes 14 and 18, we gener-
ated a 308 bp-insert Illumina whole-genome sequencing
library for whole genome sequencing. The 100 bp paired-
end sequencing of whole blood DNA generated 1,094,
407,124 individual reads with 452 million high-quality pairs.
Analysis of aligned pairs identified a cluster of reads with
ends mapping to chromosome 14 and 18. From this
analysis, 30 read pairs with high-quality mapping localized
to a single origin in the first intron of PLEKHG3 (NM
_015549.1) on chromosome 14 (chr14: 65,191,597-65,191,
620) (Fig. 2a), and 29 bp (chr14: 65,191,595-65,191,623)
were deleted at the breakpoint (Additional file 1: Figure S1).
On chromosome 18 (18q21.2), the cluster-signal split
nearly in half (14 read-pairs, and 16 read-pairs) and
mapped to two distinct locations 0.98 Mb apart (Fig. 2a).
Further analysis of reads from this region of chromosome
18 suggested an inversion of 18q21.2. This inversion
(0.98 Mb, chr18: 52,256,629- 53,200,017) encompassed
RAB27B, CCDC68, and interrupted TCF4 and DYNAP
(Fig. 2b, Additional file 1: Figure S2). The centromeric
breakpoint deleted 38.9 Kb (chr18: 52,217,704-52,256,628)
including the promoter and first exon of DYNAP tran-
script NM_173629. The telomeric breakpoint deleted 19.4
Kb (chr18: 53,200,018-53,219,411) within TCF4; this did
not delete any defined promoters or exons for transcripts
of TCF4. We confirmed the inversion breakpoints (chr18:
53,200,017) by PCR amplification and Sanger sequencing
(Fig. 2b, Additional file 1: Figure S2).
On one derivative chromosome, the portion of chromo-
some 14 centromeric to the PLEKHG3 intron 1 break-
point (chr14: 65,191,597) was joined to the breakpoint of
the inverted terminal portion of TCF4 (chr18: 53,200,017)
and the telomeric portion of 18q (Fig. 3a, Additional file 1:
Figure S2). On the second derivative chromosome, the
portion of chromosome 18 centromeric to the breakpoint
within DYNAP (chr18: 52,217,703) was joined to the por-
tion of 14q telomeric to the PLEKHG3 intron 1 breakpoint
(chr14: 65,191,620) (Fig. 3b, Additional file 1: Figure S2).




The translocation does not disrupt global gene-
expression patterns on the derivative chromosomes
(der14 and der18)
Given the observation that patients in our study did not
share the distinctive features of Pitt Hopkins syndrome
(Table 1), the syndromic form of ID associated with het-
erozygous TCF4 mutations, and the potential for trans-
located chromosomal segments to have altered gene
expression [37], we used quantitative RNA sequencing
to test for gene expression changes on chromosomes 14
and 18 (see Methods). Using RNA extracted from cul-
tured skin fibroblasts of individual II-1 and matched
controls, we generated libraries and performed 101 bp
paired-end transcriptome sequencing. This generated
114,477,006 (II-1) and 112,237,295 (control) high-quality
reads for processing and evaluation using standard bio-
informatics methodologies [34, 35]. Since chromosomal
rearrangements can disrupt the spatial connection between
a gene and its regulatory elements [38], we asked whether
there were detectable patterns of gene-misregulation on the
derivative chromosomes by computing the cross-correlation
of all genes (Pearson correlation coefficient) along chromo-
somes 14 (755 genes) and 18 (324 genes). We generated the
Pearson correlation coefficient matrix (Mi,j) for all pairs of
genes and evaluated the topological overlap along the diag-
onal for signatures of anti-correlation along the entire length
of chromosomes 18 and 14 (Additional file 1: Figure S3A,
B). Data from experiments did not reject the null hypoth-
esis, suggesting that any observed alterations in gene
expression were random. Nonetheless, to characterize fur-
ther the local expression ordering, we performed window-
modularity gene-expression analysis by comparing expres-
sion between patient and control fibroblasts [39, 40]. These
analyses also did not reveal statistically significant differ-
ences in gene-expression patterns. We concluded, there-
fore, that gene expression changes across large regions of
chromosomes 14 and 18 were either unlikely to be the
cause of this patient’s phenotype or were undetectable in
cultured fibroblasts.
Given the lack of regional gene expression changes on
chromosomes 14 and 18, we focused on gene expression
patterns at the chromosomal rearrangement breakpoints
to look for evidence of proximal-regulatory effects [38].
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We tested 14 genes around each balanced translocation
breakpoint (Table 2). Of the genes tested on chr14,
PLEKHG3 was unaltered and HSPA2, 164 kb upstream
of PLEKHG3, was marginally down-regulated at 53.2
fragments per kilobase of exon per million fragments
mapped (FPKM) vs. 120.3 FPKM for the control (P-
value < 5×10−05). Of the genes tested on chr18, DNYAP
was marginally up-regulated at 2.6 FPKM vs. 0 FPKM
(P-value < 5×10−05) and TCF4, CCDC68, and RAB27B
had reduced expression. Total TCF4 expression was 70-
80 % of the unaffected control. This level of total TCF4
mRNA was confirmed by qRT-PCR (Fig. 4a-b).
Other genomic variants do not explain the phenotype
These expression results suggested that a mutation other
than chromosomal translocation might be responsible
for the observed phenotype. To identify potential patho-





















































Fig. 2 Delineation of a balanced translocation (t(14;18)) disrupting transcription factor 4 (TCF4) using whole genome sequencing of patient DNA.
(a) Ideogram depicting the patient’s apparently balanced translocation t(14,18)(q23.2;q21.2) and normal karyotype (46, XY). The ideogram of
chromosome 18 is shaded in light blue color. (b) Inter-chromosome (red; chr18-chr14) and intra-chromosome (blue; chr18-chr18) connections
identified by whole-genome sequence analysis. Intra-chromosomal inversion (943,387 bases) on chr18 encompasses RAB27B, and CCDC68 and
interrupted DYNAP and TCF4. The inversion junctions are flanked by heterozygous deletions within TCF4 (19,394 bases (a)) and include the
promoter and first exon of DYNAP transcript NM_173629 (38,926 bases (b)). Inter-chromosome connection on chr14 disrupts PLEKHG3 resulting in
a 29 bp heterozygous deletion (c). Blue and orange arrows indicate genes on the positive and negative strand respectively. Dark blue and green
wiggles indicate read depth via whole-genome sequencing, and segmental duplications (hg19 UCSC Human genome browser) respectively.
(c) Schematic representation mechanism of the three ds-DNA breaks and genomic reorganization steps that led to the translocation event
between chromosome 14 and 18. The three main steps were: (1) a 0.94 Mb inversion (blue arch, breakpoints a and b) on chromosome 18,
followed by (2) ligation of the centromeric portion of chromosome 14 (red line, breakpoints c and a) with the telomeric q arm of chromosome
18 to yield der (14), and (3) ligation of the centromeric portion of chromosome 18 (red line, breakpoints c and b) ligation with the telomeric q
arm of chromosome 14 to yield der (18). The schematic representation of chromosomes is not to scale. The der (14) chromosome harbors a gene
fusion of PLEKHG3 (5’ untranslated region) and TCF4 (coding exons) as well as interrupted TCF4 transcript variants. The der (18) chromosome
harbors a disrupted copy of PLEKHG3; the coding potential of the gene remains intact although the promoter and first non-coding exon are
removed by the translocation
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deletions, and genomic copy number aberrations, we in-
tegrated data from the short-insert library whole-
genome sequencing and SNP chip analysis. Concordance
of array- and sequence-based SNP calling exceeded
99.2%. Bases within genes and their corresponding exons
exceeded 98 % coverage with each base sequenced >10
fold on average. We identified a total of 3.6 million sin-
gle nucleotide differences (>Q20; heterozygote/homozy-
gote ratio = 1.6; transition/transversion ratio = 2.05)
between the proband genome and the human reference
sequence (NCBI build 37; hg19). Most SNVs (>94 %)
were common variants in the general population, and
1.6 % of the SNVs localized to exonic regions. Of the ex-
onic SNVs, 461 of these were unreported or had a fre-
quency of <0.1 % in dbSNP. We ranked these 461
variants by various pathogenicity prediction software in-
cluding CDPred [41] and PolyPhen2 [42]. None of these
candidate variants showed potential to cause ID (data
not shown). In the absence of another likely strong can-
didate variant to explain the phenotype of the patients,
we concluded that the disruptions of TCF4 or PLEKHG3
remained the most likely causes.
Analysis of the sequence data from the disrupted
genes found that PLEKHG3, DYNAP, and TCF4 had no
missense changes. TCF4 had two heterozygous syn-
onymous polymorphisms, rs1261084 and rs1261085.
Altered expression of TCF4 is the most likely cause of
milder form of ID
A recent study reported a patient with a chromosomal
translocation disrupting TCF4 and a phenotype milder than
PTHS [43]. Because this report attributed the mild pheno-
type to expression of a TCF4 fusion transcript, we analyzed
cultured skin fibroblasts for expression from the TCF4
locus. The derivative chromosome fusing PLEKHG3 intron
1 (NM_001308147.1; chr14: 65,191,597) to TCF4 intron 3
(NM_001083962.1; chr18: 53,200,017) is compatible with
generation of a fusion transcript initiating at the PLEKHG3
transcriptional start site and extending from exon 4
through the remaining exons of TCF4 (NM_001083962.1,
TCF4-B+); this fusion transcript has potential to encode a
protein initiating in exon 4 of TCF4 (Additional file 1:
Figure S4). To test for such a fusion transcript, we mapped
the mate-pairs from the RNASeq data, described above,
against human reference sequence (NCBI 37, hg19) with
TopHat. Gene expression was evaluated with Cufflinks and
mate-pairs were categorized as (a) mapping to the same
gene or (b) mapping to different genes on different chro-
mosomes. This detected a gene-fusion between exon 1 of
PLEKHG3 (chr14: 65,171,193-65,171,422) and exon 4 of
TCF4 (NM_001083962.1; chr18: 53,131,307-53,131,368); 4
paired-end reads and 11 single reads spanned the junction














Fig. 3 Characterization of the breakpoints giving rise to the derivative chromosomes 14 and 18 using massively parallel whole-genome sequencing
and Sanger sequencing. (a) Characterization of derivative chromosome 14 and its breakpoints. The top panel shows a graphic of the derivative
chromosome. The middle panel shows the sequence of chromosome 14 (orange type), chromosome 18 (blue type), the derivative chromosome, and
the pileup of whole-genome sequencing reads at each junction. Forward sequence is shown as uppercase letters and reverse sequence as lowercase
letters. The mate pairs spanning the translocation junction are shown in light green (arrowheads), and those spanning the inversion junction are shown
in red (arrowheads). The lower panel shows the chromatogram for Sanger sequencing across the junction. (b) Characterization of derivative
chromosome 18 and its breakpoints. The top panel shows a graphic of the derivative chromosome. The middle panel shows the sequence of
chromosome 14 (orange font), chromosome 18 (blue font), the derivative chromosome, and the pileup of whole-genome sequencing reads at each
junction. Forward sequence is shown as uppercase letters and reverse sequence as lowercase letters. The mate pairs spanning the translocation
junction are shown in light green (arrowheads). The lower panel shows the chromatogram for Sanger sequencing across the junction
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Table 1 Comparison of our patients’ features to individuals
reported with TCF4 mutations
Feature Summary of reported patients












109 114 96 0 3










Flared nostrils 90 106 85
Large mouth 101 109 93
Tented upper lip 102 107 95
Everted lower lip 94 107 88
Hands
Long fingers 26 46 57 1 3
Single palmar
crease
52 88 59 3 3
Prominent finger
pads
31 69 45 2 3
Additional
palmar creases
5 32 16 0 3
Thumb ankylosis 10 68 15 0 3
Feet
Pes planus 15 25 60 1 1
Pes cavus 4 22 18 0 1
Overriding toes 15 38 39 0 1
Talipes equivarus2 6 24 25 0 3
Genitalia
Abnormal 21 57 37 0 1
Cryptorchidism 14 42 33 0 1
Spine




Strabismus 65 113 58 0 3
Myopia 43 86 50 2 3
Gastrointestinal
findings
17 26 65 0 3
Constipation 66 101 65




Table 1 Comparison of our patients’ features to individuals
reported with TCF4 mutations (Continued)
Growth findings 0 3
Height < 2 SD 19 80 24
Weight < 2 SD 9 58 16
OFC < − 2 SD 17 65 26
OFC on −2 SD 13 49 27
Microcephaly 56 113 50
Developmental
findings
Severe ID or DD 117 119 98 0 3
Hypotonia 69 80 86
Delayed walking 81 83 98 0 1
Walking
achieved
53 65 82 3 3
Ataxic gait 44 68 65 0 3
Absent language
or <5 words
105 108 97 0 3
Movement
anomalies
81 106 76 0 3

















Behavioral findings 0 3
Smiling/happy 86 99 87
Harm to self 21 59 36










72 116 62 0 3
Hyperventilation 54 99 55
Apnoea 35 65 54




Chronic hypoxia 3 31 10
Finger clubbing 3 33 9
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(data not shown). This analysis did not detect a fusion
transcript between TCF4 and DYNAP. RT-PCR of skin
fibroblast total RNA and Sanger sequencing of the prod-
ucts confirmed the PLEKHG3-TCF4 fusion transcript
(Fig. 4c) and the absence of a TCF4-DYNAP fusion tran-
script (data not shown). Contrary to the hypothesis that
the PLEKHG3-TCF4 fusion transcript contributed sub-
stantial TCF4 transcripts, the RNASeq analysis detected
few fusion mRNAs.
To determine if the paucity of fusion transcripts was an
artifact of cell culture, we tested cDNA derived from
peripheral blood by qRT-PCR. Quantitation of the 12
RefSeq TCF4 transcripts (Fig. 4d) showed that total TCF4
mRNA levels in the blood of the patients were 14–33 fold
higher than for unaffected controls (Fig. 4e) and that the
fusion transcripts from the derivative chromosome consti-
tuted only 2-3 % of the total TCF4 expression for all tran-
scripts (Fig. 4f). Focusing on transcripts interrupted by
the translocation (NM_001243226.1, NM_001243227.1,
NM_001243228.1, NM_001243230.1, NM_003199.2,
NM_001083962.1) (Fig. 4d), qRT-PCR of cDNA derived
from blood showed that mRNA levels for these transcript
variants, inclusive of the PLEKHG3-TCF4 fusion tran-
script, were expressed at only 10-20 % of the level of the
control (Fig. 4g). We concluded therefore that expression
of a fusion transcript did not rescue overall TCF4 expres-
sion [43].
Because TCF4 has promoters distal to the translocation
breakpoint, we hypothesize that the rescue of TCF4 expres-
sion and that the moderation of the patient phenotype
arises from increased expression of these shorter tran-
scripts. To test this, we compared RNA extracted from
blood of II-1 (UDP_4637) and III-3 (UDP_4765), PTHS
controls and unaffected controls using an nCounter Gene
expression assay with probes distinguishing many TCF4
transcripts (Additional file 1: Table S6). Compared to the
unaffected controls, the patient blood RNA had increased
levels of total TCF4 mRNA and of transcripts
(NM_001243231.1, NM_001243233.1, NM_001243232.1,
NM_001243235.1, NM_001243234.1, NM_001243236.1)
initiating downstream of the translocation breakpoint,
whereas it had decreased or unchanged levels of transcripts
(NM_001243226.1, NM_001243227.1, NM_001243228.1,
NM_001243230.1, NM_003199.2, NM_001083962.1) initi-
ating upstream of the translocation (Fig. 4h). Compared to
the unaffected controls and as predicted for nonsense me-
diated mRNA decay, the two individuals with PTHS had
decreased levels of mRNA for most TCF4 transcripts
(Fig. 4e, h).
To determine whether the upregulated transcripts arose
from the translocated chromosome, we performed digital
droplet PCR for expression of rs1261085, a SNP within
the 3′ UTR of all TCF4 transcripts and for which the pro-
positus’ father is heterozygous. Using cDNA derived from
blood of II-1, we found that half of the TCF4 mRNA was
derived from the derivative chromosome and half from
the wildtype allele (data not shown).
Discussion
We demonstrate that a chromosomal translocation inter-
rupting proximal TCF4 segregates with mild ID and de-
fines a genomic interval critical for this phenotype versus
PTHS. Additionally, we find that although such transloca-
tions can produce fusion transcripts, increased transcrip-
tion from TCF4 promoters distal to the breakpoint likely
ameliorates the phenotype, i.e. prevents the congenital
anomalies and neurologic co-morbidity typical of PTHS.
Despite the disruption of TCF4, the individuals reported
herein did not meet the diagnostic criteria for PTHS
(Table 1) [32, 44]. Using two PTHS clinical scoring sys-
tems, the affected individuals considered herein had a
clinical score of only 1 on the system of Marangi et al., in
which a minimum score of 10 is an indication for TCF4
mutation analysis [44], and they had 0 out of 20 criteria
on the system of Whalen et al. in which a score of >15 is
an indication for TCF4 mutation screening [32].
To understand better the genotype-phenotype correl-
ation, we analyzed the transcripts affected by transloca-
tions causing PTHS versus mild ID [43, 45, 46]. Using
the TCF4 structure defined by Sepp et al. [30], the trans-
location of our patient and the patient reported by Schluth-
Table 1 Comparison of our patients’ features to individuals
reported with TCF4 mutations (Continued)
Seizures (history) 44 113 39 0 3































36 41 88 1 1
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Bolard et al. suggest that disruption of all transcripts origin-
ating at and proximal to the exon 8 promoters is sufficient
to cause PTHS [46], but only disruption of transcripts
originating proximal to the exon 8 promoters associates
with mild ID. In other words, the minimal set of intact
TCF4 transcripts for mild ID are NM_001243231.1, NM_
001243233.1, NM_001243232.1, NM_001243235.1, NM_
001243234.1, and NM_001243236.1. In contrast, if tran-
scripts NM_001243231.1, NM_001243233.1 and NM_00124
3232.1 are disrupted along with transcripts NM_00124
3226.1, NM_001243227.1, NM_001243228.1, NM_001243
230.1, NM_003199.2 and NM_001083962.1, the phenotype
is PTHS [44, 46]. Affirming this genotype-phenotype
correlation, PTHS-associated missense, nonsense, splice
site, frame-shift, and deletion mutations minimally alter
the transcripts disrupted by the PTHS-associated translo-
cations [30].
Transcripts originating at and proximal to the exon 8
promoters contain a nuclear localization signal (NLS), tran-
scription activation domain (AD) 2 and the basic helix-
loop-helix domain, whereas transcripts initiating at the
exon 10 promoters do not contain an NLS. Transcripts
containing the NLS encode products predominantly local-
ized to the nucleus, whereas those products without an
NLS are distributed between the nucleus and cytoplasm
[15]. Consequently, we hypothesize that partial phenotypic
Table 2 Expression of genes near the chromosome 14 and 18 breakpoints
Chromosome 18
Gene Chromosome UDP4637 FPKM Control FPKM log (UDP/Control) p-value q-value Significant
MBD2 chr18 10.0 9.0 −0.15 0.250 0.39 no
SNORA37 chr18 0.0 0.0 0.00 1.000 1.00 no
POLI chr18 3.7 2.7 −0.47 0.001 0.00 yes a
STARD6 chr18 0.0 0.0 0.00 1.000 1.00 no
C18orf54 chr18 3.0 1.4 −1.09 0.000 0.00 yes a
DYNAP chr18 2.6 0.0 N/A 0.000 0.00 yes a
RAB27B chr18 0.6 1.7 1.52 0.000 0.00 yes a
CCDC68 chr18 0.3 1.1 2.02 0.000 0.00 yes a
TCF4 chr18 17.6 21.5 0.29 0.026 0.06 no
LOC100505474 chr18 0.0 0.0 0.00 1.000 1.00 no
TXNL1 chr18 22.5 25.7 0.19 0.155 0.27 no
WDR7 chr18 6.7 6.4 −0.08 0.563 0.70 no









TEX21P chr14 0.1 0.1 −0.04 1.00 1.00 no
MTHFD1 chr14 32.0 29.4 −0.12 0.36 0.51 no
AKAP5 chr14 0.1 0.5 2.15 0.00 0.00 yes a
ZBTB25 chr14 2.4 2.5 0.08 0.66 0.78 no
ZBTB1 chr14 13.2 14.6 0.15 0.28 0.42 no
HSPA2 chr14 53.3 120.4 1.18 0.00 0.00 yes
PPP1R36 chr14 0.3 0.3 0.16 0.71 0.81 no
PLEKHG3 chr14 2.5 3.2 0.35 0.02 0.05 yes a
SPTB chr14 0.0 0.1 0.74 1.00 1.00 no
CHURC1,CHURC1-FNTB,FNTB chr14 20.3 20.4 0.01 0.97 0.98 no
GPX2 chr14 0.0 0.0 inf 1.00 1.00 no
LOC100506321 chr14 0.0 0.1 1.83 1.00 1.00 no
MAX chr14 23.2 18.8 −0.31 0.26 0.40 no
MIR4706 chr14 0.0 0.0 0.00 1.00 1.00 no
RAB15 chr14 3.4 2.3 −0.54 0.23 0.37 no
a FPKM value too low to interpret as significant (as evaluated by cufflinks)
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Fig. 4 (See legend on next page.)
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rescue from PTHS to mild ID occurs by increased
expression of TCF4 isoforms localizing to the nucleus.
Supporting this, point mutations associated with PTHS
generally occur within or downstream of the NLS,
whereas point mutations associated with mild ID
generally occur upstream of the NLS [30, 47, 48]. An
exception to this generalization is the mutation
NM_001083962:c.[C469T];[=] (p.R157*) that alters the
first amino acid of the NLS and can cause either mild
ID or PTHS [47, 49]. We must acknowledge that ex-
pression profile of TCF4 in brain may differ from that in
other tissues and that a potential shortcoming of our
study, as well that of many others, is reliance on expres-
sion analysis of blood and skin fibroblasts.
Besides delineating a minimal set of mutated tran-
scripts for occurrence of PTHS, the translocations in
our patients and the individual reported by Kalscheuer
et al. [43] show that biallelic expression for all TCF4
transcripts is essential for full intellectual function. The
diminution of longer TCF4 isoforms is not rescued by
increased expression of the shorter isoforms. This raises
at least three possible disease mechanisms for consider-
ation: 1) AD1, which is encoded only in the longer tran-
scripts, is essential for full neural function of TCF4; 2)
the longer transcripts have promoters preferentially ac-
tive in neural tissues; and 3) the overexpression of
shorter isoforms induces mild ID. Supporting the first,
AD1 and AD2 act synergistically for transcriptional acti-
vation compared to AD1 or AD2 alone [15]. Minimizing
the likelihood of the second, although not excluding it,
transcripts initiating at the exon 10 promoters, not those
initiating proximal to exon 8, are those most highly
expressed in studied brain regions [15]. Supporting the
third, a gain-of-function disease mechanism is consistent
with prior studies of PTHS-associated TCF4 mutations
[30]. We conclude therefore that both gain- and loss-of-
function mechanisms might contribute to TCF4-associ-
ated mild ID caused by chromosomal translocation and
that expression of the full complement of TCF4 tran-
scripts at the appropriate dosage is required for full in-
tellectual function.
Related to the role of TCF4 for maintenance of intellec-
tual function and variability of expressivity within a family,
the three generations described herein provide some
insight. All three affected individuals had similar intellec-
tual disability suggesting minimal variation in expressivity.
Also, the absence of early cognitive decline in the adult
individuals suggests that TCF4 dysfunction is most detri-
mental during early brain development.
Conclusions
In summary, this study of a TCF4 translocation and its con-
sequence on TCF4 promoter usage and fusion transcript
expression provides insight into the relative roles of TCF4
isoforms in ID, highlights the potential for some TCF4 iso-
forms to partially rescue the dysmorphisms and ID charac-
teristic of PTHS, shows that the ID phenotype associated
with TCF4 mutation can be relatively consistent over gener-
ations and from childhood through adulthood. Validation of
these observations in other patients is, however, required.
Availability of supporting data
The transcriptome data set supporting the results of
this article are available in GEO repository, series
record GSE77742 (http://www.ncbi.nlm.nih.gov/geo/
query/acccgi?acc=GSE77742).
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Fig. 4 Analysis of expression of genes at the breakpoints, i.e., PLEKHG3 and TCF4. (a) Graph comparing PLEKHG3 expression between cultured skin
fibroblasts of individual II-1 and cultured skin fibroblasts of an unaffected control. Analysis was done by quantitation of transcriptome sequence reads and
is shown as fragments per kilobase of exon per million fragments mapped (FPKM). (b) Graph comparing combined levels of all TCF4 transcript variants
between cultured skin fibroblasts of individual II-1 and cultured skin fibroblasts of an unaffected control. Analysis was done by quantitation of transcriptome
sequence reads. (c) Figure showing the PLEKHG3 : TCF4 fusion transcript generated by the derivative chromosome 14. The first non-coding exon of
PLEKHG3 (3’ end chr14:65,171,422) is spliced to a coding exon of TCF4 (5’ end chr18:53,131,349). This coding exon is incorporated into TCF4 transcripts
NM_001243227.1, NM_001243226.2, NM_001243228.1, NM_001083962.1, NM_001243230.1, and NM_003199.2. Transcriptome sequencing detected the
fusion transcript in cultured skin fibroblasts (data not shown) and RT-PCR and Sanger sequencing detected it in peripheral blood. (d) Diagram showing the
12 TCF4 RefSeq transcripts aligned to chromosome 18 as annotated in GRCh37/hg19. Physical positions and TCF4 exons along chromosome 18 are shown
at the top; the exons are labeled as per Sepp et al. [15]. The breakpoint within TCF4 is shown in red. The transcript variant number is shown in parentheses
following each RefSeq accession number. nCounter probes detecting each transcript are shown in the right-hand column. (e) Graph showing the
composite mRNA level of all 12 TCF4 transcripts in the peripheral blood among individuals II-1, I-2, III-3, two individuals with Pitt-Hopkins Syndrome (PTHS)
and pooled unaffected controls. Measurement was done by qRT-PCR. (f) Graph comparing the level of PLEKHG3 : TCF4 fusion mRNA to the composite
mRNA level of all 12 TCF4 transcripts in the peripheral blood of individuals II-1, I-2, III-3, and pooled unaffected controls. Measurement was done by
qRT-PCR. (g) Graph comparing the mRNA level in peripheral blood for transcripts interrupted by the translocation (NM_001243226.1, NM_001243227.1,
NM_001243228.1, NM_001243230.1, NM_003199.2, NM_001083962.1) inclusive of the PLEKHG3-TCF4 fusion transcript. The mRNA levels were measured
among individuals II-1, I-2, III-3, two individuals with Pitt-Hopkins Syndrome (PTHS) and pooled unaffected controls by qRT-PCR. (h) Graph comparing mRNA
levels in peripheral blood for various TCF4 transcripts as assessed by nCounter Analysis. The mRNA levels were measured for individuals II-1 and III-3, two
individuals with Pitt-Hopkins Syndrome (PTHS) and pooled unaffected controls. The transcripts detected by each nCounter probe are defined in panel d
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